US EditionCanadian pharmaceutical industry alarmed after Trump floats 200 per cent tariff
UNITED STATES, JUL 10 – An urgent survey shows 79% of U.S. hospitals are stockpiling medications to mitigate cost spikes and shortages from proposed 200% tariffs on pharmaceutical imports.
- The Trump administration announced plans on July 9, 2025, to impose a 200% tariff on pharmaceutical imports, mainly targeting U.S. drug supply chains.
- This move follows an April investigation citing national security concerns over U.S. dependence on imported drugs and builds on earlier steel and aluminum tariffs.
- Pharmaceutical exports to the U.S. exceed $2 billion annually, representing over 40% of Australia's pharmaceutical export market, while Canada accounts for less than 5% of U.S. generic drug imports.
- A Black Book Research survey of 100 healthcare leaders found 79% of materials managers are stockpiling medications and 90% of hospital administrators are preparing to switch to lower-cost drug formularies.
- These potential tariffs risk higher drug costs, disrupted supply chains, and operational challenges in North America, prompting calls for accelerated industry and governmental responses ahead of a July 21 deal deadline.
19 Articles
19 Articles
Commentary: Cheap drugs from Canada can’t make America healthy
The U.S. Food and Drug Administration just announced plans to help states and Indian tribes purchase certain prescription drugs from Canada, where brand-name medicines tend to be cheaper because the government caps their price. The new guidance is part of a larger Trump administration effort to cut drug prices for Americans. But states should think twice before opening their borders to foreign drugs. Aside from being impractical, the new importa…
Canadian pharmaceutical industry alarmed after Trump hints at a 200 per cent tariff
Canada likely isn't the main target of US President Donald Trump's threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril.
Canadian pharmaceutical industry alarmed after Trump threatens 200% tariff on drug imports
WASHINGTON — Canada likely isn’t the main target of U.S. President Donald Trump’s threat to impose a 200 per cent tariff on pharmaceutical imports, an industry representative said Wednesday — but his plan could still put parts of the Canadian sector in peril.
A representative of the pharmaceutical industry says that Canada is probably not the main target of US President Donald Trump's threat when he talks about imposing 200% tariffs on pharmaceutical imports, but that his plan could nonetheless jeopardize certain sectors of the Canadian industry.
Canadian pharmaceutical industry alarmed after Trump floats 200 per cent tariff
An pharmaceutical industry representative says Canada likely isn’t the main target of U.S. President Donald Trump’s threat to impose a 200 per cent tariff on pharmaceutical imports — but his plan could still put parts of the Canadian sector in peril.
Coverage Details
Bias Distribution
- 50% of the sources lean Left
To view factuality data please Upgrade to Premium
